RBC Capital lowered the firm’s price target on Edwards Lifesciences to $80 from $82 but keeps an Outperform rating on the shares ahead of the company’s Investor Day this Thursday. The management should discuss its product and clinical pipeline in detail as well as provide a financial outlook for 2024 that the firm expects to be typically conservative ahead of the start of the year, likely encompassing consensus, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EW:
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Boeing upgraded, Shopify downgraded: Wall Street’s top analyst calls
- Edwards downgraded to Underperform from Peer Perform at Wolfe Research
- Edwards announces one-year results from CLASP IID trial
- Edwards announces ‘successful results’ from TRISCEND II trial